$OWCP: they are attracting top talent: and
Post# of 15624
(Total Views: 134)
Posted On: 03/07/2017 8:48:15 PM
$OWCP:
they are attracting top talent:
and they are planning and preparing for commercialization.
On February 5, 2017, OWC Pharmaceutical Research Corp. (the "Registrant"
appointed Dr. Sharon Rozenblat as a Senior Advisor to the Scientific Advisory Board of the Registrant's wholly-owned Israeli subsidiary, One World Cannabis Ltd ("OWC Israel".
In her capacity as Senior advisor, Dr. Rozenblat will oversee, supervise and bring to fruition the commercial application of OWC Israel's cannabinoid-based medical skin treatment, as she leads the completion of the study of psoriasis, which commenced in November 2016.
Dr. Rozenblat has served as an independent consultant to companied engaged in the field of research and development, principally involving herbal products for the pharmaceutical and raw materials industries. Dr. Rozenblat has also assisted companies in the convergence of science and the commercial exploitation of innovative products based on botanicals.
Dr. Rozenblat has over 15 years of experience in research and development of the study and application of herbal extracts for medical products mainly in the field of dermatology. From 2007 through 2015, Dr. Rozenblat served as the Chief Scientist at Kamedis Ltd., located in Tel Aviv-Yafo, Israel, an herbal-based dermatological company that was founded in 1998 for development of products to treat skin conditions. As the Chief Scientist, Dr. Rozenblat was also Director of Kamedis' R&D Department, integrating traditional herbal knowledge with advanced pharmacology for the development of herbal-based products for the treatment of a variety of human dermatological conditions.
Prior to her position at Kamedis, Dr. Rozenblat served as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial R&D Foundation (KORIL) and Israel-Singapore foundation (SIIRD) which resulted in numerous products and patents. Dr. Rozenblat was also the Scientific Director for the development of herbal extraction in an herbal production JV in Chengdu, China, during which she was involved in uncovering and utilizing agricultural elements and developing extraction techniques to create commercial products for the treatment of skin conditions.
they are attracting top talent:
and they are planning and preparing for commercialization.
On February 5, 2017, OWC Pharmaceutical Research Corp. (the "Registrant"
appointed Dr. Sharon Rozenblat as a Senior Advisor to the Scientific Advisory Board of the Registrant's wholly-owned Israeli subsidiary, One World Cannabis Ltd ("OWC Israel". In her capacity as Senior advisor, Dr. Rozenblat will oversee, supervise and bring to fruition the commercial application of OWC Israel's cannabinoid-based medical skin treatment, as she leads the completion of the study of psoriasis, which commenced in November 2016.
Dr. Rozenblat has served as an independent consultant to companied engaged in the field of research and development, principally involving herbal products for the pharmaceutical and raw materials industries. Dr. Rozenblat has also assisted companies in the convergence of science and the commercial exploitation of innovative products based on botanicals.
Dr. Rozenblat has over 15 years of experience in research and development of the study and application of herbal extracts for medical products mainly in the field of dermatology. From 2007 through 2015, Dr. Rozenblat served as the Chief Scientist at Kamedis Ltd., located in Tel Aviv-Yafo, Israel, an herbal-based dermatological company that was founded in 1998 for development of products to treat skin conditions. As the Chief Scientist, Dr. Rozenblat was also Director of Kamedis' R&D Department, integrating traditional herbal knowledge with advanced pharmacology for the development of herbal-based products for the treatment of a variety of human dermatological conditions.
Prior to her position at Kamedis, Dr. Rozenblat served as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial R&D Foundation (KORIL) and Israel-Singapore foundation (SIIRD) which resulted in numerous products and patents. Dr. Rozenblat was also the Scientific Director for the development of herbal extraction in an herbal production JV in Chengdu, China, during which she was involved in uncovering and utilizing agricultural elements and developing extraction techniques to create commercial products for the treatment of skin conditions.
(2)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
PRAY FOR DEATH